此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

HLD-0915对转移性cast割前列腺癌(MCRPC)的患者的研究

2026年11月2日 更新者:Janssen Research & Development, LLC

HLD-0915的1/2阶段研究在转移性cast割前列腺癌(MCRPC)的患者中

Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

研究概览

研究类型

介入性

注册 (估计的)

190

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Colorado
      • Colorado Springs、Colorado、美国、80909
        • 招聘中
        • Rocky Mountain Cancer Center
      • Denver、Colorado、美国、80218
        • 招聘中
        • Sarah Cannon Research Institute 1
    • Connecticut
      • New Haven、Connecticut、美国、06511
        • 招聘中
        • Yale University
    • Florida
      • Sarasota、Florida、美国、34232
        • 招聘中
        • Florida Cancer Specialists
    • Louisiana
      • Metairie、Louisiana、美国、70006
        • 招聘中
        • XCancer Research Network LCMC Health EJGH
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Dana Farber Mass General Brigham Cancer Care Inc
    • Michigan
      • Grand Rapids、Michigan、美国、49546
        • 招聘中
        • South Texas Accelerated Research Therapeutics, LLC (START)
    • Nebraska
      • Omaha、Nebraska、美国、68130
        • 招聘中
        • Urology Cancer Center, PC
    • New York
      • Long Island City、New York、美国、11101
        • 招聘中
        • Memorial Sloan Kettering Cancer Center
      • Syracuse、New York、美国、13210
        • 招聘中
        • Associated Medical Professionals
    • North Carolina
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke University Medical Center
    • South Carolina
      • Myrtle Beach、South Carolina、美国、29572
        • 招聘中
        • Carolina Urologic Research Center
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • Sarah Cannon Research Institute
      • Nashville、Tennessee、美国、37209
        • 招聘中
        • Urology Associates
    • Texas
      • Austin、Texas、美国、78758
        • 招聘中
        • NEXT Oncology
      • Houston、Texas、美国、77030
        • 招聘中
        • MD Anderson Cancer Center
    • Virginia
      • Norfolk、Virginia、美国、23502
        • 招聘中
        • Virginia Clinical Research
      • Sutton、英国、SM2 5PT
        • 招聘中
        • The Royal Marsden NHS Trust

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Patients must meet the following criteria to be eligible study participation:

Key Inclusion Criteria:

All Study Arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):

Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication

mCRPC Arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen

SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI

mHSPC arms (Phase 2 Part 2B, 2C & 2D) serum testosterone >150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA >2.0 ng/mL

Key Exclusion Criteria:

All arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):

Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day Prior or ongoing significant medical condition

mCRPC arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods

SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer

mHSPC arms (Phase 2 Part 2B, 2C & 2D) regional pelvic lymph node disease only

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:JNJ-101556143 Phase 1 Part 1 - Dose Escalation

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

实验性的:JNJ-101556143 Phase 1 Part 2 - Formulation Exploration

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Experimental: Oral JNJ-101556143

Experimental: Oral JNJ-101556143

实验性的:JNJ-101556143 Phase 2 Part 1 - Dose Optimization

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

实验性的:Phase 2 Part 2A - SOAR

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

实验性的:Phase 2 Part 2B - HSPC Expansion

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

实验性的:Phase 2 Part 2C - HSPC Expansion

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

实验性的:Phase 2 Part 2D - HSPC Expansion

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Frequency of dose-limiting toxicities (DLTs)
大体时间:21 days
21 days
Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
大体时间:21 days
21 days
Phase 1 Part 2 (formulation exploration) relative bioavailability
大体时间:22 days
22 days

次要结果测量

结果测量
措施说明
大体时间
PK Parameters
大体时间:21 days
21 days
Duration of Response (DOR)
大体时间:21 days
21 days
Radiographic Progression-Free Survival (rPFS)
大体时间:63 days
63 days
Time to Response (TTR)
大体时间:63 days
63 days
Change in PSA over time
大体时间:21 days

Including PSA50 and PSA90 response

21 days
Objective Response Rate (ORR)
大体时间:63 days

Per RECIST in evaluable patients

63 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年2月6日

初级完成 (估计的)

2028年8月17日

研究完成 (估计的)

2028年8月17日

研究注册日期

首次提交

2025年1月20日

首先提交符合 QC 标准的

2025年1月27日

首次发布 (实际的)

2025年1月30日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅